Methylation of the DCLK1 promoter region in circulating free DNA and its prognostic value in lung cancer patients

Clinical and Translational Oncology

Volumn 18, Issue 4, 2016, Pages 398-404

  Powrozek T ^a   Krawczyk, P ^a   Nicos M ^a   Kuznar Kaminska B ^b   Batura Gabryel, H ^b   Milanowski, J ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

DCLK1; DNA methylation; Free circulating DNA; Lung cancer

Indexed keywords

DOUBLECORTIN LIKE KINASE 1; PHOSPHOTRANSFERASE; UNCLASSIFIED DRUG; DCLK1 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE; TUMOR MARKER;

ADULT; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; DCLK1 GENE; DNA METHYLATION; FEMALE; GENE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROMOTER REGION; SENSITIVITY AND SPECIFICITY; SMALL CELL LUNG CANCER; SMOKING; ADENOCARCINOMA; BLOOD; CANCER STAGING; CASE CONTROL STUDY; FOLLOW UP; GENETICS; LARGE CELL CARCINOMA; LUNG TUMOR; METABOLISM; NON SMALL CELL LUNG CANCER; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TUMOR EMBOLISM;

ADENOCARCINOMA; BIOMARKERS, TUMOR; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; DNA METHYLATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROTEIN-SERINE-THREONINE KINASES; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE;

EID: 84961155174     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-015-1382-z     Document Type: Article

References (23)

1. Infante MV, Pedersen JH. Screening for lung cancer: are we there yet? Curr Opin Pulm Med. 2010;16:301–6.
2. Boiselle PM. Computed tomography screening for lung cancer. JAMA. 2013;309:1163–70.
3. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011;32:605–44.
4. Das PM, Singal R. DNA methylation and cancer. J Clin Oncol. 2004;22:4632–42.
5. Ruth EB, Knight L, Greystoke A, Blackhall FH, Hughes A, Dive C, et al. DNA methylation in circulating tumour DNA as a biomarker for cancer. Biomark Insights. 2007;2:307–19.
6. Melissa A, Edwards, Pashayar P, Neavin DR, Brown MA. Methylation in tumorigenesis, methylation—from DNA, RNA and histones to diseases and treatment. Prof. Anica Dricu (Ed.), InTech 2012; 119–135. ISBN: 978-953-51-0881-8.
7. Jin H, Ma Y, Shen Q, Wang X. Circulating methylated DNA as biomarkers for cancer detection, methylation—from DNA, RNA and histones to diseases and treatment. Prof. Anica Dricu (Ed.), InTech 2012; 137–152, ISBN: 978-953-51-0881-8.
8. Nakanishi Y, Seno H, Fukuoka A, Ueo T, Yamaga Y, Maruno T, et al. Dclk1 distinguishes between tumor and normal stem cells in the intensine. Nat Genet. 2013;45:98–103.
9. Vedeld HM, Skotheim RI, Lothe RA, Lind GE. The recently suggested intestinal cancer stem cell marker DCLK1 is an epigenetic biomarker for colorectal cancer. Epigenetics. 2014;9(3):346–50.
10. Andersen K, Boberg KM, Vedeld HM, Honne H, Hektoen M, Wadsworth CA, et al. Novel target genes and valid biomarker panel identified for cholangiocarcinoma. Epigenetics. 2012;7(11):1249–57.
11. Dreos R, Ambrosini G, Périer R, Bucher P. EPD and EPDnew, high-quality promoter resources in the next-generation sequencing era. Nucl Acids Res. 2012;41:157–64.
12. Gu C, Lu J, Cui T, Lu C, Shi H, Xu W, et al. Association between MGMT promoter methylation and non-small cell lung cancer: a meta-analysis. PLoS One. 2013;8(9):e72633.
13. Deep JS, Sidhu S, Chandel A, Thapliyal S, Garg C. Aberrant methylation in promoters of GSTP1, p16, p14, and RASSF1A Genes in smokers of North India. ISRN Pulmonol. 2012;2012: Art. ID 247631. doi:10.5402/2012/247631
14. Vaissière T, Hung RJ, Zaridze D, Moukeria A, Cuenin C, Fasolo V, et al. Quantitative analysis of DNA methylation profiles in lung cancer identifies aberrant DNA Methylation of specific genes and its association with gender and cancer risk factors. Cancer Res. 2009;69:243–52.
15. Lokk K, Vooder T, Kolde R, Valk K, Vosa U, Roosipuu R, et al. Methylation markers of early stage non-small cell lung cancer. PLoS One. 2012;7(6):e39813.
16. Wasserkort R, Kalmar A, Valcz G, Spisak S, Krispin M, Toth K, et al. Aberrant septin 9 DNA methylation in colorectal cancer is restricted to a single CpG island. BMC Cancer. 2013;30(13):398.
17. Bañez LL, Sun L, Leenders GJ, Wheeler TM, Bangma CH, Freedland SJ, et al. Multicenter clinical validation of PITX2 Methylation as a prostate specific antigen Recurrence predictor in patients with post-radical prostatectomy prostate cancer. J Urol. 2010;184:149–56.
18. Kim YJ, Yoon HY, Kim SK, Kim YW, Kim EJ, Kim YI, et al. EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling. Clin Cancer Res. 2011;17(13):4523–30.
19. Warren JD, Xiong W, Bunker AM, Vaughn CP, Furtado LV, Roberts WL, et al. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med. 2011;9:133.
20. Powrózek T, Krawczyk P, Kucharczyk T, Milanowski J. Septin 9 promoter region methylation in free circulating DNA-potential role in noninvasive diagnosis of lung cancer: preliminary report. Med Oncol. 2014;31(4):917.
21. Wu D, Xiong L, Wu S, Jiang M, Lian G, Wang M. TFPI-2 methylation predicts poor prognosis in non-small cell lung cancer. Lung Cancer. 2012;76:106–11.
22. Niklinska W, Naumnik W, Sulewska A, Kozłowski M, Pankiewicz W, Milewski R. Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC). Folia Histochem Cytobiol. 2009;47(2):275–80.
23. Sandoval J, Mendez-Gonzalez J, Nadal E, Chen G, Carmona FJ, Sayols S, et al. A prognostic DNA methylation signature for stage I non-small-cell lung cancer. J Clin Oncol. 2013;31(32):4140–7.